Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Melanoma 3Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Graft vs Host Disease 2Colitis 2Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Crohn Disease 1

Interventions

Infliximab 3Fecal Microbiota Transplantation 3vedolizumab 2Prednisone 2Methylprednisolone 2LDP-02 2Immunoglobulin G 2Disulfides 2CT-P13 2tocilizumab 1prednylidene 1fish oil triglycerides 1deltacortene 1Standard of Care 1Practice Guidelines as Topic 1Methylprednisolone Hemisuccinate 1Loperamide 1Injections 1Endoscopy 1Colonoscopy 1Cell- and Tissue-Based Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Colitis × vedolizumab × Clear all
NCT03819296 2026-03-11

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
800 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Lung Neoplasms, Urogenital Neoplasms

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡